| Autor: |
Gori, Niccolò, Ippoliti, Elena, Ferrucci, Silvia Mariel, Balato, Anna, Ortoncelli, Michela, Maurelli, Martina, Galluzzo, Marco, Munera Campos, Monica, Seremet, Teofila, Di Nardo, Lucia, Antonelli, Flaminia, Coscarella, Giulia, Conrad, Curdin, Carrascosa, Jose Manuel, Bianchi, Luca, Argenziano, Giuseppe, Ribero, Simone, Girolomoni, Giampiero, Marzano, Angelo Valerio, Chiricozzi, Andrea |
| Předmět: |
|
| Zdroj: |
Journal of the European Academy of Dermatology & Venereology; Oct2024, Vol. 38 Issue 10, pe852-e854, 3p |
| Abstrakt: |
This article discusses the use of tralokinumab, a targeted therapy, in patients with moderate-to-severe atopic dermatitis (AD) who are unresponsive, intolerant, or have contraindications to other available treatments such as dupilumab and JAK inhibitors. The study included 17 difficult-to-treat patients who had previously failed dupilumab or upadacitinib, and the results showed significant improvements in disease severity scores and physician-based assessments after treatment with tralokinumab. Adverse events were reported in 23.5% of patients, and 29.4% discontinued treatment due to ineffectiveness or adverse events. Overall, tralokinumab demonstrated a favorable clinical response in difficult-to-treat patients with AD. [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text